Harvard Bioscience appoints John Duke to board; incentive share pool increases 3.9M

HARVARD BIOSCIENCE INC

John Duke appointed to board effective June 2, 2025; will serve on audit and nominating committees.
Thomas Loewald resigned from board effective May 30, 2025; no disagreement cited.
Katherine Eade named Lead Independent Director.
Shareholders approved Amended and Restated 2021 Incentive Plan, increasing authorized shares by 3,923,000.
Non-binding advisory vote on executive compensation passed with 23.8M for vs 2.5M against.

item 5.02 item 5.07 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John D. Duke

Director

HBIO · HARVARD BIOSCIENCE INC

Effective: 2025-06-02
Filed: June 2, 2025, 7:59 PM ET

On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.

Departed

Thomas Loewald

Director

HBIO · HARVARD BIOSCIENCE INC

Effective: 2025-05-30
Filed: June 2, 2025, 7:59 PM ET

On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.

Role change

Katherine Eade

Lead Independent Director

HBIO · HARVARD BIOSCIENCE INC

Effective: 2025-06-02
Filed: June 2, 2025, 7:59 PM ET

One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John D. Duke was appointed as Director at HARVARD BIOSCIENCE INC.

Action: appointed
Role: Director

Exact text from the filing

On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas Loewald resigned as Director at HARVARD BIOSCIENCE INC.

Action: resigned
Role: Director

Exact text from the filing

On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Katherine Eade was appointed as Lead Independent Director at HARVARD BIOSCIENCE INC.

Action: appointed
Role: Lead Independent Director

Exact text from the filing

One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.

View on SEC.gov

HARVARD BIOSCIENCE INC filing history →

Source: SEC EDGAR

accession 0001171843-25-003574

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.